Gapping up
In reaction to strong earnings/guidance: GV +12.9%, SA +11.2%, CTSO +10%, DAR +9.9%, AMDA +7.5%, BSQR +7.1%, WX +5.5%, VJET +5.5%, JWN +5.4%, GOL +5.1%, AGRX +4.8%, FGEN +3.7%, JCP +3.2%, YY +3%, PAAS +2%, NBY +1.7%, SBS +1.6%, BUFF +0.8%
M&A news: WX +5.5% (enters into definitive merger agreement equal to $46 per ADS)
Select metals/mining stocks trading higher: AU +5.6%, HMY +4.1%, GOLD +2.3%, GDX +1.6%, ABX +1.3%
Other news: PBMD +64% (will receive an undisclosed clinical milestone payment, from its collaboration and licensing agreement with Novartis (NVS) relating to its Phase I IMP701 LAG-3 antibody), ONTX +31.3% (announced the submission of an investigational new drug application to the FDA for IV rigosertib as a treatment for higher-risk myelodysplastic syndromes), QTM +9.8% (reported positive data from its intranasal human abuse liability study of KP201/APAP, indicating significantly lower exposure to hydrocodone when administered intranasally; co also reported earnings), KMPH +9.6% ( reports positive data from its intranasal human abuse liability study of KP201/APAP, indicating significantly lower exposure to hydrocodone when administered intranasally), EBIO +9% (cont strength), OSGB +5.5% (co amended its credit agreement to provide additional flexibility in using proceeds from loans under the agreement to repay the $84 million in convertible notes due Nov. 15, 2015.), NVO +2.6% (Genmab A/S grants Novo Nordisk (NVO) commercial licenses to use the DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs), SD +1.9% (announces the repurchase of $250 mln of its senior unsecured notes, for $94.5 mln in cash and the exchange of $275 mln in notes for new convertible notes), FIT +1.7% (cont vol), DXCM +1.7% (favorable commentary on Thursday's Mad Money), TSLA +1.6% (priced ~2.694 mln share common stock offering at $242.00/share), ATVI +1.2% (NPD data released +6% YoY)
Analyst comments: EGO +4.7% (upgraded to Outperform at BMO Capital Markets ), CYBR +3% (upgraded to Outperform at Wells Fargo), KMI +1.8% (added to Conviction Buy list at Goldman ), MTOR +1.5% (upgraded to Buy at Longbow ), DD +1.5% (upgraded to Overweight at JP Morgan), NAV +0.6% (upgraded to Market Perform at BMO Capital Markets)